The current stock price of FLKS is 0.6068 null. In the past month the price increased by 25.11%. In the past year, price decreased by -30.65%.
Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts.
Flexpharma Inc.
31 St. James Avenue 6thFloor
Boston MA 02116
CEO: William McVicar
Phone: 617-874-1821
Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts.
The current stock price of FLKS is 0.6068 null. The price increased by 0.23% in the last trading session.
FLKS does not pay a dividend.
FLKS has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
ChartMill assigns a technical rating of 5 / 10 to FLKS. When comparing the yearly performance of all stocks, FLKS is a bad performer in the overall market: 69.29% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to FLKS. While FLKS seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months FLKS reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 55.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1208.29% | ||
| ROA | -115.76% | ||
| ROE | -135.42% | ||
| Debt/Equity | 0 |